Linked Data API

Show Search Form

Search Results

1135042
registered interest false more like this
date less than 2019-06-26more like thismore than 2019-06-26
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Spinal Muscular Atrophy: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what estimate he has made of the annual cost to the public purse of (a) the decision by NICE in May 2019 to enable people with spinal muscular atrophy to access new drugs and (b) enabling all people with relevant conditions to access those drugs; and if he will make a statement. more like this
tabling member constituency Christchurch more like this
tabling member printed
Sir Christopher Chope more like this
uin 269609 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-01more like thismore than 2019-07-01
answer text <p>The National Institute for Health and Care Excellence has advised that the total budget impact for the National Health Service at list prices to make nusinersen available for the total population with spinal muscular atrophy has been projected to be £156 million. The actual budget impact is subject to a managed access agreement and a confidential commercial agreement between NHS England and NHS Improvement and the company.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-01T15:49:02.907Zmore like thismore than 2019-07-01T15:49:02.907Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
242
label Biography information for Sir Christopher Chope more like this